Halozyme Therapeutics, Inc.
Veridion Score
Composite trend over time
Why is HALO moving today?
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for HALO.
HALO insider activity
Halozyme Therapeutics, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for HALO.
HALO contract awards, year to date.
Public federal awards linked to this ticker.
HALO lobbying filings, year to date.
Registered lobbying filings matched to Halozyme Therapeutics, Inc..